How has the fund performed?
where the fund invests
basic facts
- Launch date: February 16, 1993
- Category: share
- Type: Large & Midcap
- AUM (as on September 30, 2021): Rs 1,196 crore
- Benchmark: Nifty Large Midcap 250 Total Return Index
What is the rate
NAV (as on October 19, 2021)
- Growth Option: Rs 103.47
- IDCW: Rs 50.40
- Minimum investment: Rs 5,000
- Minimum SIP amount: Rs 500
- Expenditure Ratio (as on 31st August, 2021) (%): 2.53
- Exit Load: 1% for redemption within 364 days
fund manager: V. Srivatsa:
Tenure: 4 years, 4 months
Top 5 Sectors in Portfolio (%)
Top 5 Stocks in Portfolio (%)
Recent portfolio changes
- new entrants: Dr Reddy’s Laboratories, GR Infraprojects, HPCL, Oracle Financial Services Software, Aditya Birla Sun Life AMC
- full exhaust: Cadila Healthcare, LIC Housing Finance, Bharat Petroleum Corporation, DCM Shriram
How risky is it?
Source: Value Research
should you buy
Earlier run as Large-cap Oriented Offering (UTI Top 100), this fund was converted into large-and-mid cap category a few years back. While its midcap presence has grown now, it retains its large-cap leanings to bring in stability and liquidity. It also opts for modest investments in small-caps considering the limited opportunities in the mid-cap basket. The fund manager follows a relative value approach, avoiding paying for expensive growth names. It also invests in partially cyclical and turnaround or restructuring stories. The fund performed poorly during 2018-20, but has picked up in the last one year. Having a poor long-term track record, the fund needs to show continuous improvement in the return profile.